Results for this period
Third quarter1 January 2026–30 September 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Technology revenue increased in addition to growth in global strategic products, primarily in North America and EMEA. Core operating profit increased due to higher gross profit accompanying growth in overseas revenue and technology revenue, as well as lower research and development expenses.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 September 2026 |
| Net Sales | ¥384,947 million (YoY +10.2%) |
| Operating profit | ¥96,952 million (YoY +46.8%) |
| Ordinary income | ¥64,728 million (YoY +35.1%) |
| Profit attributable to owners of the parent | ¥51,673 million (YoY +58.5%) |
| Net income per share | ¥98.70 |
| Equity ratio | End of the current fiscal period 83.5 / End of previous period 80.6 |
| Total assets | ¥1,088,380 million |
| Net assets | ¥908,543 million |
| Cash flows from operating activities | ¥86,298 million |
| Cash flows from investing activities | ¥-26,636 million |
| Cash flows from financing activities | ¥-38,124 million |
| Cash and cash equivalents at end of period | ¥241,114 million |
| Full-year earnings forecast | Net Sales ¥520,000 million (YoY +4.7%) / Operating profit ¥130,000 million (YoY +18.4%) / Ordinary income ¥95,000 million (YoY +8.9%) / Net income ¥75,000 million (YoY +11.9%) |
| Annual Dividend Forecast | ¥62 → ¥70（+12.9%） |
| Regional sales | ¥837 hundred million (YoY -6.7%), ¥1,485 hundred million (YoY +14.3%), ¥628 hundred million (YoY +0.7%), ¥900 hundred million (YoY +33.3%) |
| Depreciation and amortization | ¥23,079 million |
| Impairment loss | ¥6,528 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Item Impairment losses and impairment reversals (gains) / Amount ¥6,528 million, Item Contract losses / Amount Not disclosed |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate Yes / Restatement Not disclosed |
| Changes in the scope of consolidation | New Not disclosed / Excluded Number of companies 1 / Company name Orchard Therapeutics Limited |
| Material subsequent events | On 6 October 2026, the first patient was dosed in a Phase I/II trial in Japan of KK4408 for autoimmune diseases. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and securities analysts |
| Issued Shares at Period-End | 525,634,500 |
| Treasury Shares at Period-End | 2,049,790 |
| Factors Behind Changes in Business Performance | Technology revenue increased in addition to growth in global strategic products, primarily in North America and EMEA. Core operating profit increased due to higher gross profit accompanying growth in overseas revenue and technology revenue, as well as lower research and development expenses. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Growth in global strategic products, primarily in North America and EMEA; higher technology revenue; increased gross profit accompanying growth in overseas revenue and technology revenue; and lower research and development expenses. Foreign exchange had a ¥19.8 billion positive impact on revenue and an ¥8.5 billion positive impact on core operating profit.